StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note published on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright dropped their price target on shares of Aptose Biosciences from $7.00 to $2.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th.

Aptose Biosciences Price Performance

APTO opened at $0.19 on Thursday. Aptose Biosciences has a fifty-two week low of $0.13 and a fifty-two week high of $2.91. The company’s 50-day moving average is $0.38 and its 200 day moving average is $0.60. The firm has a market capitalization of $3.44 million, a PE ratio of -0.06 and a beta of 1.26.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp grew its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the period. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. 26.62% of the stock is currently owned by institutional investors and hedge funds.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.